Pricing Log in Create free account
Friday 6 November 2026 Export BTCY’s income statement to Excel — free account

Biotricity Inc.

BTCY Healthcare Medical Devices

Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025.

Revenue
+10.4%
EPS
−66.7%
Free cash flow
+235.8%
Total debt
+3.48%

Quarter to June 2026, against a year earlier

0.06 0.01 +20.00%
Market cap
$10.9M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
−33.34
Beneish M
−3.24
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 87.75%

Capital & Financial Ratios $m

Size
Market Cap 10.87
Revenue ttm 16.40
Net income ttm (2.69)
Free cash flow ttm 0.16
Net debt Q 26.21
Valuation
P/E 0.00
Forward P/E 0.00
Price / sales 0.08
Forward P/S Powerpack
Price / FCF 10.51
Price / book 0.00
Financial health
Current ratio Q 0.15 (below 1: weak)
Debt / equity Q (0.75) (negative: negative equity)
Interest coverage Q 0.19
Growth
Revenue growth Q +10.40% (above 0%: growing)
Operating income growth Q −43.92% (below 0%: shrinking)
EPS, this year +31.42% (at or above 15%: strong)
EPS, next year A +72.26% (at or above 15%: strong)
Revenue, next year A +14.57% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.7×, against a ten-year median of 5.7×; over the ten years it ranged from 1.7× in 2026 to 72.5× in 2019.
P/S against its own 10 years 1.46%
10-year low 10-year high
EV/Sales against its own 10 years 1.46%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 1 0 0 0
Receivables 1 2 3 2
Inventory 2 2 1 1
Other 0 1 1 1
4 5 6 6
2024 2025 2026 Q'26
Payables 10 8 9 9
ST’ Debt 12 12 26 26
Other 1 0 2 2
23 21 37 37

Compound Annual Growth %

10y 5y 3y
Sales — 36.43% 18.40%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.08 Actual −0.04

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.11 −0.05 Beat by 0.06
Q1 FY26 −0.09 −0.03 Beat by 0.06
Q2 FY26 −0.08 −0.03 Beat by 0.05
Q3 FY26 −0.08 −0.04 Beat by 0.04

EPS $

Jun Sep Dec Mar Year
’26 (0.05) — — — —
’26 (0.03) (0.03) (0.04) (0.02) (0.11)
’25 (0.49) (0.07) (0.05) (0.06) (0.55)
’24 (0.39) (0.44) (0.34) (0.47) (1.66)
’23 (0.09) (0.54) (0.54) (0.54) (2.28)
’22 (0.90) (1.56) (0.90) (0.72) (4.02)
’21 (0.54) (0.48) (0.66) (0.90) (2.64)
Fiscal quarters ending in the months shown.

Revenue $m

Jun Sep Dec Mar Year
’26 4 — — — —
’26 4 4 4 4 16
’25 3 3 4 4 14
’24 3 3 3 3 12
’23 2 2 2 3 10
’22 2 2 2 2 8
’21 0 1 1 1 3
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 1 — — — —
’26 0 0 (1) 0 (1)
’25 (1) 0 0 0 (2)
’24 (2) (2) (1) (1) (7)
’23 (4) (4) (3) (2) (14)
’22 (3) (3) (4) (5) (15)
’21 (2) (2) (3) (4) (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 1 — — — —
’26 0 0 (1) 0 (1)
’25 (1) 0 0 0 (2)
’24 (2) (2) (1) (1) (7)
’23 (4) (4) (3) (2) (14)
’22 (3) (3) (5) (5) (15)
’21 (2) (2) (3) (4) (11)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Jun ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue — — 0 1 3 8 10 12 14 16 16 +69.5% — — — —
Gross margin, % — — 15.04 34.27 37.60 59.74 56.46 69.27 76.61 80.94 81.47 +65.9 pt
EBT (8) (9) (9) (11) (15) (29) (19) (14) (8) (2) (3) (12.3%)
EBT margin, % 0.00 0.00 (2,157.73) (780.62) (457.67) (380.78) (193.57) (116.84) (61.07) (15.03) (16.41) (15.0) pt
Net income (8) (9) (9) (11) (15) (29) (19) (14) (8) (2) (3) (12.3%)
Per share, $
Per share, $ Revenue 0.00 0.00 0.07 0.24 0.54 1.01 1.11 1.34 0.64 0.59 0.71 n/m
Earnings (1.74) (1.80) (1.52) (1.84) (2.64) (4.02) (2.28) (1.66) (0.55) (0.11) (0.14) (26.4%)
Cash flow (0.87) (0.97) (0.94) (1.31) (1.77) (2.00) (1.56) (0.74) (0.11) (0.03) 0.01 (32.2%)
Capex 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow (0.87) (0.97) (0.94) (1.31) (1.77) (2.01) (1.56) (0.74) (0.11) (0.03) 0.01 (32.2%)
Book value (1.02) 0.03 (0.32) (0.50) (1.09) (0.28) (2.29) (3.50) (1.49) (1.27) (1.53) +2.5%
Shares, m 4 5 6 6 6 8 9 9 22 27 26 +22.8%
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — 76.29 24.69 26.56 13.49 2.51 1.07 0.53 0.41 0.08 18.2
P/B — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
EV/Sales — — 78.39 25.50 27.28 13.74 4.30 2.87 2.33 2.07 1.68 19.6
EV/FCF — — (3.09) (4.60) (8.33) (6.92) (3.05) (5.14) (13.33) (44.16) 209.38 (11.1)
Cash, $m
Cash, $m Operating cash flow (4) (5) (5) (8) (11) (15) (14) (7) (2) (1) 0 (16.8%)
Capex — — — — — 0 — — — — 0 —
Free cash flow (4) (5) (5) (8) (11) (15) (14) (7) (2) (1) 0 (16.8%)
Balance, $m
Balance, $m Working capital (4) 0 (2) (2) (6) 10 (6) (18) (16) (31) (32) +24.3%
Net debt 1 (1) 1 1 2 2 17 22 25 27 26 +42.0%
Shareholders’ equity (4) 0 (2) (3) (7) (2) (20) (31) (32) (35) (35) +25.8%
Returns, %
Returns, % ROA (2,886.99) (1,229.41) (1,210.07) (907.77) (510.78) (286.22) (168.48) (239.76) (206.19) (51.76) (57.12) +2,835.2 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE 184.76 409.52 1,071.00 474.03 334.63 673.20 177.66 58.19 37.62 9.38 9.75 (175.4) pt
People
People Employees — — — — — — — — 46 46 — 0.0%
Revenue/emp, $m — — 0.00 0.00 0.00 0.00 0.00 0.00 0.30 0.35 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

Biotricity Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HSCS HeartSciences Inc. $13.3M — (loss-making) — (loss-making) −46.15% (below 0%: shrinking) n/m +18.18% (above 0%: growing) 61.90% (139,957.14%) Compare
PETV PetVivo Holdings, Inc. $12.9M — (loss-making) — (loss-making) +13.48% (above 0%: growing) n/m +40.13% (above 0%: growing) 66.14% (476.54%) Compare
ITOC iTonic Holdings Ltd. $12.4M — — — — — — — Compare
PAVM PAVmed Inc. $12.4M — (loss-making) — (loss-making) +450.00% (above 0%: growing) n/m −125.63% (below 0%: shrinking) (269.70%) (21,278.79%) Compare
MODD Modular Medical, Inc. $12.2M — (loss-making) — — n/m −5.61% (below 0%: shrinking) 0.00% 0.00% Compare
IRIX IRIDEX Corporation $11.9M — (loss-making) — (loss-making) −7.41% (below 0%: shrinking) n/m +130.24% (above 0%: growing) 34.19% (8.19%) Compare
SINT SINTX TECHNOLOGIES, INC. $11.5M — (loss-making) — (loss-making) +952.88% (above 0%: growing) n/m +47.37% (above 0%: growing) 62.19% (74.66%) Compare
BTCY Biotricity Inc. $10.9M — (loss-making) — (loss-making) +10.40% (above 0%: growing) n/m +235.83% (above 0%: growing) 82.55% 3.70%
AEMD Aethlon Medical, Inc. $8.5M — (loss-making) — (loss-making) +335.00% (above 0%: growing) n/m −11.13% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $12.3M — — +174.24% — +18.18% 34.19% (74.66%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 5 August 2024

Ownership

Directors and executive officers, together 10.10%
Sohaira Siddiqui 8.08%
Mohammad Siddiqui 8.00%
Mohamed Abdi 7.54%
Rizwana Siddiqui 7.54%
Rizwan Rahman 7.54%
Waqaas Al-Siddiq 6.92%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Biotricity Inc. (BTCY) Latest News

12 Feb

Impact 4 · · GuruFocus.com

11 Feb

Impact 4 · · GlobeNewswire

5 Feb

Impact 3 · · GlobeNewswire

23 Dec

Impact 4 · · Zacks

15 Nov

Impact 4 · · GuruFocus.com
Impact 4 ·

14 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

7 Nov

Impact 3 · · GlobeNewswire

9 Sep

Impact 4 ·

3 Sep

Impact 4 · · GlobeNewswire

19 Aug

Impact 4 · · Zacks

15 Aug

Impact 4 · · Zacks

14 Aug

Impact 4 · · GlobeNewswire

17 Jul

Impact 4 · · GlobeNewswire

15 Jul

Impact 4 · · GlobeNewswire

8 Apr

Impact 4 ·

12 Mar

Impact 4 ·

20 Feb

Impact 4 ·

17 Feb

Impact 4 · · GlobeNewswire

15 Jan

Impact 4 · · PR Newswire

27 Dec

Impact 4 · · PR Newswire

3 Dec

Impact 3 ·

13 Nov

Impact 4 · · GlobeNewswire

17 Oct

Impact 4 · · ACCESSWIRE

3 Oct

Impact 4 · · ACCESSWIRE

26 Sep

Impact 4 · · ACCESSWIRE

19 Sep

Impact 4 · · ACCESSWIRE

21 Aug

Impact 4 · · ACCESSWIRE

26 Jul

Impact 3 · · ACCESSWIRE
stockrow.com/BTCY · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com